Axsome Therapeutics, Inc. (AXSM)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $10.88B
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Latest financial period: June 30, 2026
Filed with the SEC: August 10, 2026
Estimated earnings date: November 2, 2026
Profit #1443 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 2.1% | 1.6% | 1.5% | 1.6% |
Growth #62 of 1484 companies
Payout #1117 of 1484 companies
Safety #1457 of 1484 companies
Price #1363 of 1484 companies
